Carboplatin Uses, Dosage, Side Effects and Interactions
Kyxata
Kyxata came 36 years after Paraplatin (August 2025) as an injection. The FDA rates no generic as a substitute for it.
Paraplatin
Paraplatin was the first carboplatin product the FDA approved, in March 1989. The FDA now lists it as discontinued; generic carboplatin is still listed.
Carboplatin is a platinum-based chemotherapy medicine given by injection to treat advanced ovarian carcinoma (ovarian cancer), both as first treatment and when the cancer has come back after earlier chemotherapy.
Quick links
Ask Anything About CarboplatinType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Carboplatin in Short
- Drug class Platinum-based Drug How the FDA classifies it
What it treatsCarboplatin treats advanced ovarian cancer. It is used in two situations. Initial treatment of advanced ovarian cancer, as part of a combination with other approved chemotherapy medicines. Carboplatin with cyclophosphamide is one established combination. Kyxata is also used this way in adults.
- How you get it Prescription only
- Comes asInjection (into a vein)Available strengths
- 50 mg/5 mL
- 80 mg/8 mL
- 150 mg/15 mL
- 450 mg/45 mL
- 500 mg/50 mL
- 600 mg/60 mL
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
- Generic launchApril 2045 Our estimate for the first generic of Kyxata
The Pharmacist’s Take
Carboplatin is a platinum chemotherapy drug that attaches to DNA inside cells and links its strands, so the cells cannot copy themselves and die; on the U.S. market since about 1989, with FDA-approved generics listed, it is a mainstay for advanced ovarian cancer, both as first treatment with other chemotherapy and when the cancer returns. It is usually easier to tolerate than its older relative cisplatin, but most people notice tiredness, some nausea and falling blood counts. Its boxed warning covers serious, sometimes life-threatening allergic reactions (anaphylaxis) that can start within minutes of an infusion in any cycle, so tell the nurse at once about itching, rash, wheezing or faintness.
Key Takeaways From the HelloPharmacist Team
- Expect a clinic IV infusion on day 1 of each cycle, about every 4 weeks, usually up to 6 cycles for first treatment.
- Plan on a blood test before every cycle, because your counts must recover first and your kidney function guides the dose.
- Call your oncology team right away for fever, chills, or unusual bleeding or bruising, signs that low blood counts are causing trouble.
- Take the antinausea medicine prescribed for after treatment on schedule, rather than waiting for nausea, and report vomiting you cannot control.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Carboplatin.
Kyxata can cause serious, life-threatening allergic reactions, including anaphylaxis. These can happen within minutes of an infusion, during any cycle. The label says treatment should be stopped or withheld for severe reactions and appropriate treatment given. Signs include rash, hives, itching, wheezing, low blood pressure and trouble breathing. Care teams give it where emergency equipment is available.
Patient Information Guide for Carboplatin
What It’s Used For
Carboplatin is used for ovarian cancer in these situations:
- Carboplatin injection: initial treatment of advanced ovarian cancer in combination with other approved chemotherapy, such as cyclophosphamide.
- Carboplatin injection: palliative (symptom-relieving) treatment of ovarian cancer that returned after earlier chemotherapy, including after cisplatin.
- Kyxata (intravenous): in adults, initial treatment of advanced ovarian cancer as part of a combination regimen.
- Kyxata (intravenous): in adults, as a single agent for ovarian cancer that returned after earlier chemotherapy.
How It Works
Carboplatin is a platinum-based drug that binds to DNA and forms cross-links between its strands. These cross-links stop cells from copying and reading their DNA. That triggers processes that lead to cell death.
It works much like cisplatin, but it changes into its active form more slowly. That difference is linked to differences in potency.
Drug Class
Drug Class
- Platinum-based Drug
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Platinum-based Drug
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Carboplatin in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Carboplatin in the FDA’s index.
From our Patient Information GuideCarboplatin is a platinum-based drug that binds to DNA and forms cross-links between its strands. These cross-links stop cells from copying and reading their DNA. That triggers processes that lead to cell death. Read How Carboplatin Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Platinum-containing Compounds
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Platinum compounds
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Carboplatin is given into a vein by a healthcare professional, so there is no food guidance and no missed doses to make up at home. Treatment usually runs in cycles of about 4 weeks, with a dose on day 1.
- Combination treatment for first-line use is usually up to 6 cycles.
- Single-agent treatment for recurrent cancer continues until the disease progresses or side effects become unacceptable (per the Kyxata label).
- Doses may be based on body size or on kidney function, and are adjusted according to blood counts.
Follow your prescriber and the product label. Call your care team if you miss an appointment.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Ovarian cancer
Adults with ovarian cancer that came back after earlier chemotherapy Usual dose 360 mg/m2 IV on day 1 every 4 weeks
- 360 mg/m2 IV on day 1 every 4 weeks (alternatively see Formula Dosing)
Good to know
Not repeated until neutrophil count is at least 2,000 and platelet count is at least 100,000
IV means given into a vein (intravenous).
Adults with advanced ovarian cancer not yet treated Usual dose 300 mg/m2 of carboplatin IV on day 1 every 4 weeks
Step by step
- Carboplatin 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing)
- Cyclophosphamide 600 mg/m2 IV on day 1 every 4 weeks for 6 cycles
Good to know
Not repeated until neutrophil count is at least 2,000 and platelet count is at least 100,000
IV means given into a vein (intravenous).
Adults with advanced ovarian cancer not yet treated · Kyxata 300 mg/m2 Usual dose 300 mg/m2 on Day 1 every 4 weeks
- Kyxata 300 mg/m2 OR AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously with cyclophosphamide 600 mg/m2 intravenously on Day 1 every 4 weeks for each cycle, up to six cycles or until disease progression or unacceptable toxicity
Good to know
For older adults, calculate dose based on AUC
Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →
Adults with ovarian cancer that came back after earlier chemotherapy · Kyxata 360 mg/m2 Usual dose 360 mg/m2 on Day 1 every 4 weeks
- Kyxata 360 mg/m2 OR AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously on Day 1 every 4 weeks for each cycle until disease progression or unacceptable toxicity
Good to know
For older adults, calculate dose based on AUC
Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →
Adults with kidney problems, creatinine clearance 41 to 59 mL/min Usual dose 250 mg/m2 on day 1
Good to know
Applies to the initial course; later doses adjusted to bone marrow suppression
Adults with kidney problems, creatinine clearance 16 to 40 mL/min Usual dose 200 mg/m2 on day 1
Good to know
Applies to the initial course; later doses adjusted to bone marrow suppression
Adults, including older adults, previously treated Dose 4 mg/mL
- Total Dose (mg) = (target AUC) × (GFR + 25)
- Target AUC 4 mg/mL · min to 6 mg/mL · min
Good to know
Dose is in mg, not mg/m2; formula dosing should be used in elderly patients
GFR means glomerular filtration rate, a measure of how well the kidneys work.
Adults with mild kidney problems · Kyxata 89 mL No dose reduction
Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →
Adults with kidney problems, creatinine clearance 41 to 59 mL/min · Kyxata 59 mL Usual dose 250 mg/m2 on Day 1
Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →
Adults with kidney problems, creatinine clearance 16 to 40 mL/min · Kyxata 40 mL Usual dose 200 mg/m2 on Day 1
Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →
Special Situations
If your test results change during treatment
Your doctor checks your test results during treatment and decides whether to change, pause or stop your dose. Never change your dose on your own.
-
Kyxata: Neutropenia, grade ≥ 4 ANC ≤ 0.5 x 10 9 / L, dose based on body surface area
Interrupt Kyxata until ≤ Grade 1; reduce dose by 25%
-
Kyxata: Thrombocytopenia, grade ≥ 3 platelet count ≤ 50 x 10 9 / L, dose based on body surface area
Interrupt Kyxata until ≤ Grade 1; reduce dose by 25%
ANC means absolute neutrophil count, the number of infection-fighting white blood cells.
Side Effects
Many people have side effects, and most are monitored with blood tests.
Common side effects
- Low blood counts (low platelets, white cells and red cells/anemia)
- Nausea and vomiting
- Stomach pain, diarrhea or constipation
- Tingling or numbness in hands and feet
- Tiredness and weakness
- Hair loss
- Low levels of salts such as sodium, potassium, calcium and magnesium
- Changes in liver or kidney blood tests
- Low electrolytes (sodium, potassium, calcium, magnesium)
When to get medical help
- Get help right away for signs of a severe allergic reaction: rash, hives, itching, wheezing, trouble breathing, or dizziness or faintness. These can happen within minutes of an infusion.
- Tell your care team about fever, chills or signs of infection, since low white cells can make infections serious.
- Report unusual bleeding or bruising, which can come from low platelets.
- Report severe or uncontrolled vomiting.
- Report new numbness, tingling or hearing changes.
- Report vision loss, which has happened with doses higher than recommended.
- Report pain, redness or swelling at the injection site.
Warnings and Precautions
- Serious allergic reactions can happen within minutes, especially after earlier platinum treatment or after 6 cycles.
- Bone marrow suppression can cause severe infections or bleeding. Blood counts are checked before each cycle.
- Hemolytic anemia and hemolytic-uremic syndrome are rare, serious conditions. Treatment should stop at the first signs.
- Severe vomiting can occur and is worse after previous emetogenic (vomiting-causing) therapy.
- Nerve problems are more likely in people over 65 or previously treated with cisplatin.
- Vision loss and severe liver problems have occurred with doses above those recommended.
- Hearing loss has been reported in children at higher doses or with other hearing-toxic drugs.
- It can harm an unborn baby.
Interactions
Carboplatin can add to the effects of other medicines.
- Aminoglycoside antibiotics: higher risk of kidney and hearing problems.
- Other kidney-harming drugs: carboplatin may increase kidney effects.
- Phenytoin or fosphenytoin: levels may drop, which may worsen seizures.
- Other bone marrow-suppressing drugs or radiation: blood count effects may add up.
Interactions Listed in the FDA-Approved Label
From the Carboplatin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Nephrotoxic compoundsWhat happensThe renal effects of nephrotoxic compounds may be potentiated by carboplatin.
-
Phenytoin/fosphenytoinWhat happensA decrease in phenytoin serum levels has been observed with concurrent carboplatin, which may lead to exacerbation of seizures.
Read the label’s full interactions text
Drug Interactions The renal effects of nephrotoxic compounds may be potentiated by carboplatin. A decrease in phenytoin serum levels has been observed with concurrent administration of carboplatin and phenytoin/fosphenytoin. This may lead to exacerbation of seizures.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use if you have had a severe allergy to cisplatin, other platinum drugs, or mannitol.
- Not for severe bone marrow depression or significant bleeding.
- Tell your doctor about kidney problems, since dose changes may be needed.
- Pregnancy: it can harm a baby. Pregnancy status should be checked first and effective contraception used.
- Breastfeeding: Kyxata advises not breastfeeding during treatment and for 1 week after.
- Older adults: higher risk of low platelets and nerve problems. Doses are based on kidney function.
- Children: safety and effectiveness have not been established for Kyxata.
Overdose
There is no known antidote for overdose. Expected problems are bone marrow suppression and liver toxicity, and loss of vision or hearing loss in children have been reported at high doses. Kyxata is removed by dialysis, and patients are monitored closely and given supportive care.
Half-Life and How Your Body Processes It
Carboplatin levels in the blood fall in two phases after an infusion. Early half-lives were about 1 to 2 hours and later ones about 2.6 to 5.9 hours. Carboplatin itself is not bound to plasma proteins, though platinum from it binds irreversibly to proteins and clears slowly (half-life at least 5 days).
The kidneys do most of the clearing. In people with good kidney function, about 71% of a dose is in the urine within 24 hours. Kidney function strongly affects clearance, so doses are lowered when kidney function is reduced.
Storage
Unopened vials of carboplatin injection are stable to the date indicated on the package when stored at 20° to 25°C (68° to 77°F) . PROTECT FROM LIGHT.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Carboplatin: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Carboplatin — the kind of thing our pharmacy team would talk through with you at the counter.
What is carboplatin used for?
How is carboplatin given, and how often?
What happens if I miss a carboplatin appointment?
What side effects should I expect, and when should I call?
Can I take carboplatin if I have kidney problems?
Is carboplatin safe during pregnancy?
Is carboplatin available over the counter?
When was carboplatin first available?
Who makes carboplatin?
What is the brand name of carboplatin?
What is the generic name of Kyxata?
What drug class is carboplatin?
Is there a generic version of carboplatin?
What strengths does carboplatin come in?
Is there a carboplatin shortage?
Where can I read the carboplatin prescribing information (package insert)?
Is carboplatin gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Carboplatin
Skip the scrolling. Ask in your own words and get an answer from Carboplatin’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Carboplatin’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Carboplatin on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Carboplatin Forms and Strengths (How It Comes)
Carboplatin comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Carboplatin inactive ingredients by manufacturer.
Injection
How this form is used
- Carboplatin injection is used for initial treatment of advanced ovarian cancer with other approved chemotherapy, and for ovarian cancer that returned after earlier chemotherapy.
- Kyxata is used in adults for initial treatment of advanced ovarian cancer as part of a combination, and alone for recurrent ovarian cancer.
- Carboplatin injection is usually given as an infusion lasting 15 minutes or longer.
- Carboplatin injection must not contact needles or IV sets with aluminum parts.
- Kyxata is given intravenously on day 1 of each cycle, about every 4 weeks, in a setting where emergency resuscitation equipment is available.
- Kyxata patients receive antinausea medicine before each infusion.
Show 1 more strength Show fewer strengths
Carboplatin on the U.S. Market: Products, Makers and Brands
How Carboplatin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
11 companies list 34 Carboplatin product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1989. The one brand name in the directory today is Kyxata; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (7) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Carboplatin Is Used (Medicaid Data)
How many Carboplatin prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Carboplatin prescribed? Of the 1,682 medications we measure, Carboplatin ranks #698 by Medicaid prescriptions — more than 59% of them.
Utilization by Carboplatin product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
carboplatin 10 MG/ML Injectable Solution
20 of 69 listed NDCs had Medicaid claims. RxNorm 597195
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 20 of the 69 listed Carboplatin NDCs had Medicaid claims.
Compare Carboplatin Products
A representative set of FDA-listed product records for Carboplatin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mg/mL | Intravenous | Accord Healthcare, Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Apotex Corp. | ANDA | View NDC → |
| 80 mg/8 mL | Intravenous | AVYXA Pharma, LLC | NDA | View NDC → |
| 500 mg/50 mL | Intravenous | AVYXA Pharma, LLC | NDA | View NDC → |
| 10 mg/mL | Intravenous | BPI Labs LLC × 4 listings | ANDA | View NDC → |
| 50 mg/5 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 150 mg/15 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 450 mg/45 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 600 mg/60 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Gland Pharma Limited × 4 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Hospira, Inc. × 5 listings | ANDA | View NDC → |
| 50 mg/5 mL | Intravenous | Natco Pharma USA LLC | ANDA | View NDC → |
| 150 mg/15 mL | Intravenous | Natco Pharma USA LLC | ANDA | View NDC → |
| 450 mg/45 mL | Intravenous | Natco Pharma USA LLC | ANDA | View NDC → |
| 600 mg/60 mL | Intravenous | Natco Pharma USA LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Teva Parenteral Medicines, Inc. × 4 listings | ANDA | View NDC → |
| 50 mg/5 mL | Intravenous | Teyro Labs Private Limited | ANDA | View NDC → |
| 150 mg/15 mL | Intravenous | Teyro Labs Private Limited | ANDA | View NDC → |
| 450 mg/45 mL | Intravenous | Teyro Labs Private Limited | ANDA | View NDC → |
| 600 mg/60 mL | Intravenous | Teyro Labs Private Limited | ANDA | View NDC → |
Showing 34 of 34 products — FDA National Drug Code Directory. See every product, package size and price: browse all 34 Carboplatin NDCs →
Carboplatin Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Carboplatin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Carboplatin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Carboplatin FDA Approval History
How Carboplatin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Carboplatin Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Carboplatin recalls since July 2021.
✅No Carboplatin recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Carboplatin in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 1
- Forms in current FDA listings
- 1 of 1
RxCUI 40048 -
Dose form (SCDF) Injectable SolutionIn current FDA listings
RxCUI 378363Its strength (SCD)-
10 mg/mL
RxCUI 597195
-
10 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Carboplatin Supply and Shortage Status
Whether Carboplatin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Carboplatin Brand Names
Carboplatin has 2 brand names on record: Kyxata and Paraplatin. Kyxata is in the FDA’s product directory today; Paraplatin is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Carboplatin: Manufacturers and Labelers
11 companies list Carboplatin products with the FDA. By number of product records, the largest are Hospira, Inc., BPI Labs LLC, Eugia US LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Carboplatin Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Avyxa Pharma, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →